Current Pharmacologic Treatment of Lower Urinary Tract Symptoms

Andersson, Karl‐Erik

doi:10.1007/978-1-4939-0853-0_13

Cited by 2 publications

(3 citation statements)

References 777 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this ‘adverse effect’ could also be considered advantageous in the setting of overactive bowel or functional diarrhoeal states, and possibly even in IBS. Antidepressants (including duloxetine, imipramine and amitriptyline) have a long history of clinical use in the management of OAB and urinary incontinence 169 and afford an opportunity to concurrently treat OAB and certain central sensitization syndromes in carefully selected patients, such as those with fibromyalgia 170 or IBS 168 . Finally, sacral neuromodulation has direct effects on bladder and bowel function and is indicated for the treatment of faecal incontinence, in addition to OAB 171 .…”

Section: Implications For Oab Treatmentmentioning

confidence: 99%

Does central sensitization help explain idiopathic overactive bladder?

et al. 2016

View full text Add to dashboard Cite

The pathophysiological mechanisms underlying overactive bladder syndrome (OAB) can include dysfunction of sensory pathways of the peripheral and central nervous systems, resulting in bladder hypersensitivity. Central sensitization describes an induced state of spinal hypersensitivity that is associated with a variety of chronic pain disorders that share many attributes with OAB, albeit without the presence of pain. As such, the concept of central sensitization might be relevant to understanding the mechanisms and clinical manifestations of OAB syndrome. An understanding of the pathophysiology and clinical manifestations of central sensitization, and the evidence that supports a role of central sensitization in OAB, including the potential implications of mechanisms of central sensitization for the treatment of patients with OAB could provide a novel approach to the treatment of patients with this disease. Such an approach would be especially relevant to those patients with central sensitization-related comorbidities, and has the potential to improve the outcomes of these patients in particular.

show abstract

Section: Implications For Oab Treatmentmentioning

confidence: 99%

Does central sensitization help explain idiopathic overactive bladder?

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Muscle relaxants as a class are commonly used to treat spasticity and musculoskeletal disorders, with well-documented effectiveness in chronic spastic musculoskeletal pain, multiple sclerosis and spinal cord injuries. 3 4 Baclofen, tizanidine and dantrolene are approved to treat spasticity, though baclofen withdrawal can be life-threateningly severe. 5 Baclofen and tizanidine are centrally acting and block GABA B receptors found in the spinal cord or brainstem, 6 7 while dantrolene directly inhibits muscle contraction by reducing the release of calcium from the skeletal muscle sarcoplasmic reticulum.…”

Section: Introductionmentioning

confidence: 99%

Skeletal muscle relaxants as adjunctive pain control following cardiothoracic surgery: a systematic review protocol

Kabir,

Whaley,

Fernandez

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionMultimodal pain control following cardiothoracic surgery remains a focus in international guidelines. We hypothesise that non-depolarising skeletal muscle relaxants can prove to be a useful adjunct for this population.Methods/analysisThis systematic review will focus on human adult studies of pain control using muscle relaxants within 1 week following cardiac and thoracic surgery available in PubMed, Cochrane Central, Web of Science and EMBASE. Target studies will have a primary focus on measured effects on quality of pain control and reduction in opioid usage. Studies that include non-depolarising skeletal muscle relaxants given during cardiothoracic surgery or in the week after will be included. Study selection will be in keeping with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Procedures and agents used will be analysed together, and a meta-analysis will be conducted then compared with current therapies recommended in international practice guidelines.Ethics and disseminationFormal ethical approval will not be required as primary data will not be collected. The results will be disseminated through peer-reviewed publication, conference presentation and lay press.PROSPERO registration numberCRD42023397917.

show abstract

Current Pharmacologic Treatment of Lower Urinary Tract Symptoms

Cited by 2 publications

References 777 publications

Does central sensitization help explain idiopathic overactive bladder?

Does central sensitization help explain idiopathic overactive bladder?

Skeletal muscle relaxants as adjunctive pain control following cardiothoracic surgery: a systematic review protocol

Contact Info

Product

Resources

About